ANTIVACCINE MISINFORMATION ABOUT RATE OF ADVERSE EFFECTS AND TOXICITY OF VACCINES


Cite item

Full Text

Abstract

Two widely known antivaccine inventions are discussed: «vaccination is accompanied by adverse effects, which exceeded complications of respective infections on frequency and severity» and «vaccines represent appalling conglomerate of toxic substances, which is unnaturally to administer to children». Informational and psychological nature of dissemination of these inventions is analyzed. On the basis of recent literature data conclusion was made about the absence of real toxicity (including neurotoxicity), carcinogenicity, allergenicity and autopathogenicity of phenol, folmaldehyde, aluminium hydroxide, Twin 80, squalen (MF59) and ethylmercury in concentrations found in vaccines of national immunization schedule.

Full Text

АНТИПРИВИВОЧНАЯ ДЕЗИНФОРМАЦИЯ ОТНОСИТЕЛЬНО ЧАСТОТЫ ПОБОЧНЫХ ЭФФЕКТОВ И ТОКСИЧНОСТИ ВАКЦИН
×

About the authors

A. N Mats

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

A. V Goldstein

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

References

  1. Барлетт С., ван Дамм П. Поведенческие аспекты и вакцинация против гепатита В. Центр ВОЗ по профилактике и контролю вирусных гепатитов, Антверпен, 2000.
  2. Кузьменко Л.Г., Тюрин Н.А., Овсянников Д.Ю. Патология вакцинального процесса у детей. Вест. Росс. ун-та др. нар. Сер. Медицина. 1999, 2: 40—60.
  3. Мац А.Н. Антипрививочное движение в России. Вакцинация. Новости вакцинопрофилактики. 2007, 4-6: 1011.
  4. Семенов Н.В. Биохимические компоненты и константы жидких сред и тканей человека. М., Медицина, М., 1971.
  5. Червонская Г.П., Кравченко А.Т., Рунова В.Ф. и др. Цитотксическое действие химических веществ, содержащихся в виде примесей в некоторых медицинских иммунобиологических препаратах. Журн. микробиол. 1988, 12: 8590.
  6. Andrews N., Miller E., Grant A. et al. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004, 114 (3): 584-591.
  7. Berman R.F., Pessah I.N., Mouton P.R. et al. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice. Toxicol. Sci. 2008, 101(2):294—309.
  8. Carlson B.C., Jansson A.M., Larsson A. et al. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am. J. Pathol. 2000, 156(6):20572065.
  9. Centers for disease control and prevention (CDC). Deaths associated with hypocalcemia from chelation therapy — Texas, Pennsylvania, and Oregon, 2003—2005. Morb. Mortal. Wkly. Rep. 2006, 55 (8): 204-207.
  10. Coors E.A., Seybold H., Merk H.F., Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann. Allergy Asthma Immunol. 2005, 95 (6): 593-599.
  11. Del Giudice G., Fragapane E., Bugarini R. et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vac. Immun. 2006, 13 (9): 1010-1013.
  12. Fombonne E., Zakarian R., Bennett A. et al. Pervasive developmental disorders in Montreal, Quebec, Canada: Prevalence and links with immunizations. Pediatrics. 2006, 118(1): e139-50.
  13. Gosselin R.E., Hodge H.C., Smith R.P., Gleason M.N. Clinical toxicology of commercial products. Baltimore, Williams and Wilkins, 1976.
  14. Gruis K.L., Teener J.W., Blaivas M. Pediatric macrophagic myofasciitis associated with motor delay. Clin. Neuropathol. 2006, 25 (4): 172-179.
  15. Hem S.L. Elimination of aluminum adjuvants. Vaccine. 2002, 20: 3: S40-43.
  16. Heron J., Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004, (3): 577-583.
  17. Hviid A., Stellfeld M., Wohlfahrt J., Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003, 290 (13):1763- 1766.
  18. IARC monographs on the evaluation of carcinogenic risks to humans,volume 88 Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2ol., WHO, Lyon, 2006.
  19. Ip P., Wong V., Ho M. et al. Mercury exposure in children with autistic spectrum disorder: casecontrol study. J. Child. Neurol. 2004, 19 (6): 431-434.
  20. Jefferson T., Rudin M., Di Pietrantonj C. Adverse events after immunisation with aluminiumcontaining DTP vaccines: systematic review of the evidence. Lancet Infect. Dis. 2004, 4 (2): 84-90.
  21. Keith L.S., Jones D.E., Chou C.H. Aluminum toxicokinetics regarding infant diet and vaccinations. Vaccine. 2002, 20 (3): S13-17.
  22. Kuroda Y., Akaogi J., Nacionales D.C. et al. Distinctive patterns of autoimmune response induced by different types of mineral oil. Toxicol. Sci. 2004, 8 (2): 222-228.
  23. Kuroda Y., Nacionales D.C., Akaogi J. Auto- immunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed. Pharmacother. 2004, 58 (5): 325-337.
  24. Lach B., Cupler E.J. Macrophagic myofasciitis in children is a localized reaction to vaccination. J. Child. Neurol. 2008, 23 (6): 614-619.
  25. Lindblad E.B. Aluminium adjuvants — in retrospect and prospect. Vaccine. 2004, 22 (27—28): 3658-3668.
  26. Madsen K.M., Lauritsen M.B., Pedersen C.B. et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003, 112 (3; 1): 604-606.
  27. Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J. Appl. Toxicol. 2001, 21: 1-5.
  28. Matyas G.R., Rao M., Pittman P.R. et al. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J. Immunol. Methods. 2004, 286 (1—2):47-67.
  29. McCormick M., Bayer R., Berg A. Report of the Institute of Medicine: Immunization safety review—vaccines and autism. Washington, DC: National Academy Press, 2004.
  30. Parker S.K., Schwartz B., Todd J., Pickering L.K. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004, 114 (3): 793-804.
  31. Pichichero M.E., Gentile A., Giglio N. et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Ibid. 2008, 121 (2): e208-214.
  32. Plotkin S., Orenstein W., Offit P. (ed.). Vaccines. Philadelphia, 2008.
  33. Polysorbate 80: Contact allergy in a child: case report. Reactions. 2003, 1 (954): 13.
  34. Price K.S., Hamilton R.G. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007, 28 (3): 313-319.
  35. Risher J.F., Amler S.N. Mercury exposure: evaluation and intervention the inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning. Neurotoxicology. 2005, 26 (4): 691-699.
  36. Satoh M., Kuroda Y., Yoshida H. et al. Induction of lupus autoantibodies by adjuvants. J. Auto- immun. 2003,21 (1): 1-9.
  37. Stehr-Green P., Tull P., Stellfeld M. et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am. J. Prev. Med. 2003 25 (2): 101-106.
  38. Schechter R., Grether J.K. Continuing increas- es in autism reported to California’s develop- mental services system: mercury in retrograde. Arch. Gen. Psychiatry. 2008, 65 (1): 19-24.
  39. Thomas A. Pharmacovigilance and Traceability. Geneva, 2006.
  40. Thompson W.W., Price C., Goodson B. et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N. Engl. J. Med. 2007, 357 (13): 1281-1292.
  41. Toxicological profile for phenol, U.S.Departament of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, September 2008.
  42. Toxicological profile for aluminum. agency for toxic substances and disease registry, September 2008.
  43. Toxicology and carcinogenesis studies of Polysorbate 80. NTP TR No. 415, NIH Publication No. 92-31246, January 1992.
  44. Verdier F., Burnett R., Michelet-Habchi C. et al. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey. Vaccine. 2005, 23 (11): 1359-1367.
  45. Verstraeten T., Davis R.L., DeStefano F. et al. Safety of thimerosal-containing vaccines: a twophased study of computerized health maintenance organization databases. Pediatrics. 2003,112 (5): 1039-1048.
  46. Weber G., Gross J., Kromminga A. et al. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J. Am. Soc. Nephrol. 2002, 13 (9): 2381-2383.
  47. World Health Organization. Adverse events following immunization: causality assessment. Geneva, 2008.
  48. http://www.bausch.com/en_US/msds/general_ ec/07SootheXPEmollient6-25.pdf.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Mats A.N., Goldstein A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies